NCT01115803 2019-02-05A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsEli Lilly and CompanyPhase 1 Terminated29 enrolled 19 charts
NCT01402089 2016-02-02Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCantonal Hospital of St. GallenPhase 4 Completed54 enrolled
NCT00101348 2014-06-11Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/2 Completed66 enrolled